Regenxbio(RGNX.US)

Last Updated 19:00:00 ET
longbridge loading

16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences

prnewswire·
US
RGNX
+0.18%
US
PBE
+0.11%
US
SBIO
-1.24%
prnewswire·
US
RGNX
+0.18%
US
PBE
+0.11%
US
SBIO
-1.24%

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

Market Beat·
US
RGNX
+0.18%
US
LABU
-2.35%
US
FBT
+0.54%
Market Beat·
US
RGNX
+0.18%
US
LABU
-2.35%
US
FBT
+0.54%

Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)

Tip Ranks·
US
RGNX
+0.18%
US
FBT
+0.54%
US
IBB
+0.10%
Tip Ranks·
US
RGNX
+0.18%
US
FBT
+0.54%
US
IBB
+0.10%

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

fidelity·
US
RGNX
+0.18%
US
IBB
+0.10%
US
BIB
+0.05%
fidelity·
US
RGNX
+0.18%
US
IBB
+0.10%
US
BIB
+0.05%

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga_article·
US
QUCY
-23.64%
US
STAA
+0.90%
US
ALP
-0.36%
benzinga_article·
US
QUCY
-23.64%
US
STAA
+0.90%
US
ALP
-0.36%

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

benzinga_article·
US
RGNX
+0.18%
US
PBE
+0.11%
US
XBI
-0.69%
benzinga_article·
US
RGNX
+0.18%
US
PBE
+0.11%
US
XBI
-0.69%

RegenXBio Advances RGX-202 With Positive Phase III Results

Tip Ranks·
US
RGNX
+0.18%
Tip Ranks·
US
RGNX
+0.18%

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News

StockTitan·
US
RGNX
+0.18%
StockTitan·
US
RGNX
+0.18%

REGENXBIO shares are trading lower after the company reported worse-than-expected Q1 financial results.

benzinga_article·
US
RGNX
+0.18%
benzinga_article·
US
RGNX
+0.18%
© 2026 Longbridge｜Disclaimer